(1384 ) 60-67 1 (H. pylori, C. pneumonia, Hrepes Simplex Virus, Cytomegalovirus) * 4 3 2 1 ** 7 6 5 5 4 1 3 4 5 6 7 2 HDL :. CMV HSV-1. - 25 ( 49/2 50/8) 1791 : ATPIII NCEP.. 44/9 54/6 : P=0/0001) (OR=1/47 P=0/004) (OR=2/01 P = 0/003) HSV (OR=1/77 P=0/0001) (OR=1/62 P=0/001) (OR=1/69. (OR=1/99 P=0/007) CMV :. HSV-1 CMV 84/4/20 : 84/3/3 : 84/1/18 : :. * 3631 :. 0771-2528587 **
61 /.(5-18) 25-64 NCEP ATP III. -. : :I. :II. - : ( I 3000 25 ).( 150000 ( ) 156/61 481/05 X :.(1) (WHO). NCEP ATP III.(2) 102 ) 3 88 150 40 HDL 50 110 ( 130/85.(3) ATP III WHO.(3) NCEP.(4). CMV HSV-1
1384 / 1 / 62 Selectra 2 autoanalyzer» «(Vital specific,the Netherlands ). colorimetric method enzymatic ) (glucose oxidase ( Pars Azmun Inc;Tehran, Iran) HDL. ( oxidase phenol aminoantipyrine cholesterol) -3 enzymatic method glycerol -3 phosphate ) (oxidase phenol aminoantipyrine LDL.. ( Friedman Formula) : ( National cholesterol Education ) Program's Adult Treatment panel III =ATP 2001 (III : 3 88 : -1 102 150 : -2 40 :HDL -3 50 : -4 110 : -5 130 85.(2).. I 25 =<. - 12-14. : (. 1382-3. 7:30 9:30. «WHO MONICA».. «Standimeter» ) BMI.(. ECG.
63 /. 50/8) 910 1791 ( 49/2) 881 ( 54/6..(P=0/005) 44/6 1.(P=0/0001). CMV. (P<0/05) CMV.(P>0/05). CMV. HSV-1 (P=0/025) HSV-1. (P=0/001).(P=0/005) (P=0/008). (P=0/004).(P=0/001) (P=0/001).(P=0/01). (P=0/005).(2) ATP(III) ECG 1.2 1.1. -5.3 7.1 4.1-4.4 1.3 IHD. 5.1 ECG. ( : IgG (EIA) DRG. EIU 45 EIA IgG RADIM. 15 UR/ml EIA CMV IgG RADIM IgG. 10 RU/ml EIA HSV-1. RADIM : ( 2*2 Chi-square «Two-Tailed test». P > 0/05.. IHD-ECG. - ( 55-64 45-54 35-44 25-34) IBM. SPSS 9.05 (SPSS Inc;Chicago,IL)
1384 / 1 / 64 (1 P CI OR P 0/003 1/27-3/16 2/01 %85/3 %92/1 N.S N.S 0/7-2/15 1/23 %93/6 %94/8 0/007 0/0001 1/28-2/23 1/69 %30/0 %42/2 0/0001 0/004 1/12-1/92 1/47 %55/1 %64/4 0/001. LDC. (injury). (foam cell) (fatty streaks)... T (mast cell)....(31) CI OR 0/73-1/54 1/06 %83/3 %84/2 HSV-1 1/21-3/27 1/99 %89/2 %94/3 CMV 1/34-2/32 1/77 %37/8 %51/9 1/23-2/13 1/62 %56/6 %67/9.(P=0/001).(P=0/001) CMV.(P=0/001) (P>0/05) CMV.(P=0/008) HSV-1 (P=0/003) HSV-1 2.(P>0/05). HSV-1. CMV
65 / 1996..(36)..(37). IL-6 TNF- α..(37) :.. HSV1 CMV.. (5-18 30) HSP-60 (anti-hsp-60) (Natinal Health And Nutrition 24 NHANES Examinatin Survey)(III).(32).(31) CRP hs-crp(high Sensitive-CRP) CRP 24 14719. CRP.(33) CRP 2.(34) Proinflammatory TNF-α (Tumor Necrosis Factor-α) CRP A IL6(Interleukin-6) (Adiponectin) Leptin. ) CRP (IL6..(35) HDL-C.
1384 / 1 / 66 CRP IL6. CRP IL6 IL6.. IL6.(35) IL6 TNF-α....(38 37) (hypercoagulation) CRP (adhesion).(25).(38) IL6 TNF-α ۀ. TNF-α. TNF-α (Serine) (IRS-1) (IRS-1).(40 39) References: 1. Ferrannini E, Haffner SM, Mitchell BD, et al. Hyperinsulinemia. the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22. 2. Expert Panel on Detection,Evaluation and Treatment of High Blood Cholesterol in Adults :Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. 3. Bonora E, Kiechl S,Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. Diabetes Care 2003; 26:1251-7. 4. McNeill AM, Rosamond WD, Cynthia J, et al.the Metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005;28:385-90. 5. Fabricant CG, Fabricant J. Minick CR, et al. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983;42:2476-9. 6. Shih SCH, Pullman EP, Jao KJ. Genetic selection, general characterization, and history of atherosclerosis-susceptible and resistance Japanese quail. Atherosclerosis 1983;49:41-53. 7. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA 1990;263:2204-07. 8. Adam E, Melnick JL, Probstfield JL, et al. High levels of cytomegalovirus antibody in patients
67 / requiring vascular surgery for atherosclerosis. Lancet 1987;2:291-3. 9. Melnick JL, Adam E, DeBakay ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993; 14(suppl 1):30-8. 10. Yamashiroya HM,Ghoch L,Yang R, et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988;130:71-9. 11. Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus /herpesvirus and carotid atherosclerosis: the ARIC Study. J Med Virol 1993;42:33-7. 12. Saikku P, Mattila K, Nieminen MS,et al. Serologic evidence of an association of a novel Chlamydia,TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6. 13. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.Ann Intern Med 1992;116:273-8. 14. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonesterated coronary artery disease. JAMA 1992;268:68-72. 15. Kuo CC, Grayston JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995;92:6911-14. 16. Havlik RJ, Blackwelder WC, Kaslow R, et al. Unlikely association between clinically apparent herpesvirus infection and coronary incidence at older ages: the Framingham Heart Study. Arteroisclerosis 1989;9:877-80. 17. Grayston GT,Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995;92:3397-400. 18. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary artery disease. Br Heart J 1994;71:437-9. 19. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109:II- 2-II-10. 20. Ford ES,Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults:findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9. 21. Ridker PM,Buring JE,Cook NR, et al. C-reactiv protein, the metabolic syndrome, and risk of incident cardiovascular events.an 8 year follow up of 14719 initially healthy American women. Circulation 2003; 107:391-7. 22. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?eur Heart J 2002;23:831-4. 23. Sridevi D,Rosenson RS, Ishwarlal J, et al. Metabolic syndrome:an appraisal of the proinflamatory and pro-coagulant status. Endocrinol Metab Clin N Am Part1 2004;33:431-53. 24. Howard G, O leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. Circulaiton 1996;93:1809-17. 25. Fernandez- Real JM, Wifredo R. Insulin resistance and chronic cardiovascular inflamarory syndrome. Endocrine Rev 2003;24:278-301. 26. Espinola-Klein C, Ruppricht SJ, Blankenberg S, et al. Are morphological or functional changes in the carotid artery wall associated with C. pneumonia, H.pylori, CMV or HSV infections? Stroke 2000;31:2127-33. 27. Aristo V. A look at infectious agents as a possible causative factor in cardiovascular disease. Science 2003;34:6-11. 28. Vercellotti GM. Microbs,inflammation and atherosclerosis: will old pathology lessons guide new therapies? Trance Am Clin Climatol Assoc 2001;112:215-22. 29. Engelman JA, Berg AH, Renee Y, et al. Tumor necrosis factor -a mediated insulin resistance, but not de differentiation, is abrogated by MEKl/2 inhibitors in 3T3-L1 adipocytes. Molecular Endocrinol 2000;14: 1557-69. 30. Hotamisligil GS, Murray DL, Choy LN, et al. Tumor necrosis factor-a inhibits signaling from the insulin receptor.biochemistry 1994;91:4854-8.